Abstract

Research Article

Triple negative breast cancer: Early stages management and evolution, a two years experience at the department of breast cancer of CHSF

Bouzid Nassima, Darido Jessie*, Diari Jed, Dussour Chloe, Ezenfis Joel, Cahn Virginie, Guekeu Steven and Rigonnot Luc

Published: 30 June, 2020 | Volume 3 - Issue 1 | Pages: 065-078

Breast cancer is the most common cancer in women and is a major public health problem. It is divided into several subtypes, including triple negatives. The general objective of our study is to establish the profile and the management of patients with triple negative breast cancer over a period of 2 years, operated in our department.

During our study period, triple-negative breast cancers accounted for 10% of our population. The most affected age group ranges from 50 to 60. The majority of patients in our sample are pauciparous. In the group of patients who received hormone therapy, it was mainly HRT for 4 to 6 years. 96.77% of patients consulted a health worker within 3 months of the discovery of the signs. Adenopathies are frequently present at the time of diagnosis. 93.54% of the cases have an invasive ductal carcinoma. Triple negative cancers are essentially poorly differentiated. Triple-negative cancer has a high rate of cell renewal. In our study, neoadjuvant chemotherapy is mostly indicated for triple-negative breast cancers ≥ 30 mm at diagnosis and a delayed lumpectomy is then performed in 23.52% of the patients. For tumors of < 30 mm size, a lumpectomy is performed immediately in 76.47% of the patients, followed by adjuvant chemotherapy.

Mastectomy was performed in 45.16% of patients; it was mainly indicated in front of a large tumor size associated with a small breast volume, then multifocal breast tumors. Breast reconstruction was performed in 21.42%. Radiation therapy is indicated in the majority of patients, postoperatively. In our population, 11 patients were proposed to have an oncogenetic survey; it was mainly indicated based on the Manchester criteria in front of a young age and a family history of cancer. There are two BRCA 1 mutations, one BRCA 2 mutation, and one case of absence of mutation. The therapeutic intake in case of a mutation is directed towards a prophylactic bilateral mastectomy and adnexectomy, proposed at the age of 40. Two patients had presented triple negative recurrences of their already treated breast cancer; first case PDL1 positive PD-L1 ≥ 1% treated with immunotherapy combined with chemotherapy (atezolizumab/abraxane) while the second and second PDL1 negative treated with chemotherapy alone.

Despite their low frequency, triple negative breast cancers represent a subgroup marked by pejorative characteristics, a reserved prognosis, with limited treatment options.

Read Full Article HTML DOI: 10.29328/journal.cjog.1001052 Cite this Article Read Full Article PDF

Keywords:

Triple negative; Breast cancer oncogenetics; Prognosis; Demographics mastectomy; Hormonotherapy

References

  1. Anthony G, Renaud S, Emmanuelle CJ. Cancer du sein triple-négatif: caractéristiques histocliniques et moléculaires, prise en charge et perspectives thérapeutiques Bull Cancer. 2013; 100.
  2. Portha H, Jankowski C, Cortet M. Tumeurs localisées du sein triple négatives en 2016: définitions et prise en charge Gynécologie Obstetrique & Fertilité. 2016; 44: 492–504.
  3. Victoire W, Agnes C, Caroline D. Influence des facteurs hormonaux sur le pronostic des cancers du sein triple négatifs, Gynécologie Obstétrique Fertilité et Sénologie. 2019.
  4. Thakur KK, Bordoloi D, Kunnumakkara AB. Alarming Burden of Triple-Negative Breast Cancer in India, Clinical Breast Cancer. 2017; 18: 393-399. PubMed: https://pubmed.ncbi.nlm.nih.gov/28801156/
  5. Rosalind P, Candelaria, Beatriz E, et al. Imaging features of triple-negative breast cancers according to androgen receptor status, Eur J Radiol. 2019; 114: 167–174. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31005169
  6. Ibrahim K, Bendahhou K, Saile R. Antécédent familial et âge de survenue du cancer du sein chez les patientes triples-négatives ou non triples-négatives prises en charge au centre Mohammed VI pour le traitement des cancers, Revue d’Épidémiologie et de Santé Publique 64S. 2016; S137–S161.
  7. James M, Dixit A, Robinson B. Outcomes for Patients with Non-metastatic Triple-negative Breast Cancer in New Zealand. Clin Oncol. 2019; 31: 17e24. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/30274766
  8. Kallel I, Rebaı M, Khabir A. What common biomarkers characterize a triple-negative profile in breast cancer? Pathologie Biologie. 2015; 63: 224–229. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26300241
  9. Ming Y, Chloé R, Amel R. Radiotherapy in triple-negative breast cancer: Current situation and upcoming strategies. Critical Reviews in Oncology / Hematology.2018; 131: 96–101. PubMed: https://pubmed.ncbi.nlm.nih.gov/30293712/
  10. Anatomie de la glande mammaire. UVMaF. 2011; 21.
  11. Kamina P. Anatomie opératoire, gynécologie-obstétrique. Maloine. 2000; 318.
  12. Nkondjock A, Ghadirian P. Facteurs de risque de cancer du sein, medecine/sciences. 2005; 21: 175-180.
  13. Classification en six catégories des images mammograhiques en fonction du degré de suspicion de leur caractère pathologique (en dehors des images construites et des variantes du normal) correspondance avec le système birads de l’American college of radiology (ACR), ANAES / Service des recommandations et références professionnelles. Février. 2002.
  14. Boisserie L, Mac G, Debled M. Aspects radiologiques des cancers du sein triple négatifs: à propos de 73 cas, Journal de Radiologie Diagnostique et Interventionnelle. 2012; 93: 196-203.
  15. Cottu P, Delaloge S. Cancers et pathologies du sein attitudes diagnostiques et thérapeutiques, protocoles de traitement, Institut Curie & Gustave-Roussy. 2016-2017.
  16. Haute autorité de santé, Tumeur maligne, affection maligne du tissu lymphatique ou hématopoïétique Cancer du sein. Institut national du cancer. 2010.
  17. Gonçalves A. Chimiothérapie néoadjuvante des cancers du sein HER2-positifs et triplenégatifs. Bull Cancer. 2016; 103: S76–S89.
  18. Vijayakrishna K. Gadi E, Davidson. Practical Approach to Triple-Negative Breast Cancer. Am Society Clin Oncol. 2017; 13: 293-300. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28489980
  19. Adamo V, Ricciardi G, Placido S, et al. Management and treatment of triple negative breast cancer patients from the NEMESI study: an Italian experience. Eur J Cancer. 2012; 48: 642867. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21757335
  20. Redondo C, Gago-Dominguez M, Ponte S, Colucci G, Conte P, et al. Breast feeding, parity and breast cancer subtypes in a Spanish cohort. PLoS One. 2012; 7: e40543. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22792365
  21. Wojcinski S, Soliman A, Schmidt J, Makowski L, Degenhardt F, et al. Sonographic features of triple-negative and nontriple-negative breast cancer. J Ultrasound Med. 2012; 31: 1531-1541. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23011616
  22. Qiu J, Xue X, Li R, Wang JD. Clinicopathological features and prognosis of triple-negative breast cancer: a comparison between younger (<60) and elderly (>/¼60) patients. Eur J Cancer Care (Engl) 2016. 25:1065-75. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26122025
  23. Widodo I, Dwianingsih E, Triningsih E, Utoro T, Soeripto. Clinicopathological features of Indonesian breast cancers with different molecular subtypes. Asian Pac J Cancer Prev. 2014; 15: 6109-6113. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25124582
  24. Bauer K, Brown M, Cress R, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer. 2007; 109: 1721-1728. PubMed: https://pubmed.ncbi.nlm.nih.gov/17387718
  25. Gueye M, Gueye S, Mbaye M. Aspects cliniques et pronostiques des cancers du sein triple négatifs à l’unité de sénologie du CHU Le-Dantec de Dakar. J Afr Cancer. 2013; 5: 42-47.
  26. Hashmi AA, Edhi MM, Naqvi H, Faridi N, Khurshid A, et al. Clinicopathologic features of triple negative breast cancers: an experience from Pakistan. Diagn Pathol. 2014; 9: 43. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24581278
  27. Stead LA, Lash TL, Sobieraj JE, Chi DD, Westrup JL, et al. Triple-negative breast cancers are increased in black women regardless of age or body mass index. Breast Cancer Res. 2009; 11: R18. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19320967
  28. Jack RH, Davies EA, Renshaw C, Tutt A, Grocock MJ, et al. Differences in breast cancer hormone receptor status in ethnic groups: a London population. Eur J Cancer. 2013; 49: 696-702. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23058788
  29. Chen HL, Ding A, Wang FW. Prognostic effect analysis of molecular subtype on young breast cancer patients. Chin J Cancer Res. 2015; 27: 428-436. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26361413
  30. Vona-Davis L, Rose D, Hazard H, Howard-McNatt M, Adkins F, et al. Triple-negative breast cancer and obesity in a rural Appalachian population Cancer Epidemiol Biomarkers Prev. 2008; 17: 3319-3324. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19064545
  31. Jarroudi A, Abda N, Afqir S. le surpoids est-il un facteur pronostique dans le cancer du sein triple négatif ? revue d’épidémiologie et de santé publique. 2016; 64: S137-S161.
  32. Ronny M, Chu Q, Li BDL, Burton GV, Ampil FL, et al. Does obesity have an effect on outcomes in triple negative breast cancer? J Surg Res. 2013; 184: 253-259. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23768767
  33. Shaheenah D, Xiudong L, Jennifer K. Impact of Body Mass Index on Survival Outcome Among Women With Early Stage Triple-Negative Breast Cancer. Clin Breast Cancer. 2012; 12: 364-372. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23040004
  34. Ademuyiwa F, Groman A, O’Connor T, Ambrosone C, Watroba N, et al. impact of body mass index on clinical outcomes in triple negative breast cancer. Cancer. 2011. 117: 4132. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21387276
  35. Yang X, Sherman X, Rimm D, Jolanta Lissowska, Louise A Brinton, et al. Differences in risk factors for breast cancer molecular subtypes in a population based study. Cancers Epidemiol Biomarkers Prev. 2007; 16: 439-443. PubMed: https://pubmed.ncbi.nlm.nih.gov/17372238/
  36. Barnard M. Established breast cancer risk factors and risk of intrinsic tumor subtypes, Biochimica et Biophysica Acta. 2015; 1856: 73-85. PubMed: https://pubmed.ncbi.nlm.nih.gov/26071880/
  37. Stacoffe M. Etude de l'hétérogénéité des cancers du sein triple négatif et de l’impact de l’infiltration tumorale par les lymphocytes (TILs), des lymphocytes T CD4+, CD8+, des lymphocytes T régulateurs et des macrophages sur le pronostic de 105 patientes traitées en situation adjuvante au CHU de Tours, thèse de médecine, faculté de medecine de tours, Université François-Rabelais, 2016.
  38. Phipps A, Malone K, Porter P, Daling JR, Li CI. Reproductive and hormonal risk factors for postmenopausal luminal, HER2- overexpressing and triple negative breast cancer. Cancer. 2008; 113: 1521-1526. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2587413/
  39. Millikan R, Newman B, Tse C, Moorman PG, Conway K, et al. Epidemiology of basal-like breast cancer. Breast cancer Res Treat. 2008; 109: 123-139. PubMed: https://pubmed.ncbi.nlm.nih.gov/17578664
  40. Collaborative group on hormonal risk factors in breast cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 without the disease. Lancet. 2002; 12: 1059-1069. PubMed: https://pubmed.ncbi.nlm.nih.gov/12133652/
  41. Ma H, Wang Y, Sullivan H, Weiss L, Marchbanks PA, et al. Use four biomarkers to evaluate the risk of breast cancer subtypes in the women’s contraceptive and reproductive experiences study. Cancer Res. 2010; 70: 575-587. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2807992/
  42. Dolle J, Daling J, White E, Brinton LA, Doody DR, et al. Risk factors for triple negative breast cancer in women under the age of 45 years, Cancer Epidemiol Biomarkers Prev. 2009; 18: 1157-1166. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2754710/
  43. Kabat GC, Kim M, Phipps AI, Li CI, Messina CR, et al, Smoking and alcohol consumption in relation to risk of triple Negative breast cancer in a cohort of postmenopausal women, Cancer Causes Control. 2012. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3100347/
  44. Valeria V, Aurélie A, Pierre O. Cancer du sein : risque génétique, Imagerie de la Femme. 2016; 26: 95-104.
  45. Benoit S. Cancer du sein triple négatif: étude rétrospective monocentrique chez 465 patientes prises en charge au centre Renne Gauducheau, thèse de medecine, université de Nantes. 2016.
  46. principales recommandations de prise en charge des femmes porteuses d’une mutation de BRCA 1 ou BRCA 2, Institut National du Cancer. 2009.
  47. Steward L, Conant L, Gao F, Margenthaler JA. Predictive Factors and Patterns of Recurrence in Patients With Triple Negative Breast Cancer. Ann Surg Oncol. 2014; 21: 2165-2171. PubMed: https://pubmed.ncbi.nlm.nih.gov/24558065/
  48. Vikas P,Borcherding N,Zhang W. The Clinical Promise of Immunotherapy in Triple-Negative Breast Cancer. Cancer Manag Res. 2018; 10: 6823-6833. PubMed: https://pubmed.ncbi.nlm.nih.gov/30573992
  49. Schmid S. Adams HS, Rugo A, Schneeweiss CH, Barrios H, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018; 379: 2108-21. PubMed: https://pubmed.ncbi.nlm.nih.gov/30345906/

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More